<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ARNA</title>
	<atom:link href="http://www.stockbloghub.com/tag/arna/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(OREX) Orexigen Therapeutics Lifeline for Contrave</title>
		<link>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937</link>
		<comments>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937#comments</comments>
		<pubDate>Sat, 24 Sep 2011 19:00:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83937</guid>
		<description><![CDATA[Orexigen Therapeutics, Inc.&#8216;s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration&#8217;s (FDA) office of new drugs (OND) regarding the development path for its obesity candidate Contrave. Following the OND’s decision, Orexigen decided to resume the development of Contrave. Orexigen is looking to gain approval for Contrave for the treatment of obesity, including weight loss and maintenance of weight loss. The company has a collaboration agreement with Takeda for the development and commercialization of Contrave in the US, Canada and Mexico. Story so far…. In January 2011, Orexigen received a complete response letter (CRL) from the FDA for Contrave. The FDA  expressed concerns regarding the long-term cardiovascular safety profile of Contrave and asked Orexigen to conduct an additional study. The FDA requested a randomized, double-blind, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus First Quarter 2011 Loss Narrower than Expected</title>
		<link>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458</link>
		<comments>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458#comments</comments>
		<pubDate>Fri, 06 May 2011 01:39:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73458</guid>
		<description><![CDATA[Vivus Inc.’s (VVUS) first quarter 2011 loss of 12 cents per share was narrower than the Zacks Consensus loss Estimate by 3 cents and the year-ago loss (from continuing operations) by 9 cents. The narrower loss in the reported quarter was attributable to a decline in operating costs. Vivus did not generate any revenues in the reported quarter as in the previous year. Operating expenses at Orexigen declined 35.6% to approximately $9.9 million. Research &#38; development (R&#38;D) expenses plummeted 56% to $4.5 million. General and administrative (G&#38;A) expenses increased marginally to $5.4 million in the reported quarter. The significant reduction in R&#38;D expenses was primarily attributable to the lower spend on clinical development of obesity candidate Qnexa and erectile dysfunction (ED) candidate, avanafil as both of them are nearing approval. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/vvus-vivus-first-quarter-2011-loss-narrower-than-expected/73458/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226</link>
		<comments>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226#comments</comments>
		<pubDate>Thu, 03 Feb 2011 17:21:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[COR]]></category>
		<category><![CDATA[Cortex Pharmaceuticals Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66226</guid>
		<description><![CDATA[Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and behavioral causes of obesity, has been co-developed with Japan’s Takeda. While issuing the CRL, dated January 31, 2011, the FDA stated that it is concerned about the long-term cardiovascular safety profile of the obesity candidate and has asked Orexigen to conduct an additional study. The request to conduct an additional study means further bad news for Orexigen as this will push up its research and development expenses. Orexigen intends to meet the FDA to discuss the issues raised in the CRL. The decision ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus Seeks EU Nod for Qnexa</title>
		<link>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722</link>
		<comments>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722#comments</comments>
		<pubDate>Tue, 28 Dec 2010 06:46:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63722</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric diet), including weight loss and maintenance of weight loss. Qnexa’s approval would be a major positive for Vivus. The obesity market represents huge commercial potential for Vivus. Obesity is a worldwide epidemic and is estimated to affect about 150 million adults in the EU. A smooth review process could result in Qnexa receiving EU approval in late 2011. Currently available treatments for obesity include orlistat, sold by Roche (RHHBY) as Xenical and by GlaxoSmithKline (GSK) as Alli (available over-the-counter). A commercially available prescription product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Arena Pharmaceuticals is Denied FDA Approval for Obesity Candidate Drug</title>
		<link>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417</link>
		<comments>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:44:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56417</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company’s obesity candidate lorcaserin citing tumor-related safety concerns. The US regulatory authority issued a complete response letter (CRL) stating that the efficacy of the drug in non type II diabetes obese patients was found to be marginal. The FDA asked the company to submit the final study report of the BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in DiabetesMellitus) study which evaluated the efficacy of lorcaserin against placebo in obese and overweight patients suffering from type II diabetes. Arena intends to present top-line data from the study shortly and complete the study report by the end of this year. The FDA stated further that it may ask ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/arna-arena-pharmaceuticals-is-denied-fda-approval-for-obesity-candidate-drug/56417/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Removes Obesity Drug Meridia From Market</title>
		<link>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707</link>
		<comments>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707#comments</comments>
		<pubDate>Wed, 13 Oct 2010 02:14:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54707</guid>
		<description><![CDATA[Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs&#8217; decision was based on a request made by the US Food and Drug Administration (FDA). The FDA’s request was based on data from a post-marketing study (SCOUT &#8211; Sibutramine Cardiovascular OUTcome Trial), which showed that patients treated with Meridia experienced a 16% increase in the risk of cardiovascular events (non-fatal heart attack/stroke, the need to be resuscitated once the heart has stopped, and death) compared to placebo. Results also showed that the difference in weight loss between the Meridia and placebo arms was small. In mid-Sep 2010, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had conducted a meeting to review the drug. While 8 panelists were in favor of removing the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/abt-abbott-labs-removes-obesity-drug-meridia-from-market/54707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) FDA to Review Vivus Drug</title>
		<link>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446</link>
		<comments>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446#comments</comments>
		<pubDate>Thu, 15 Jul 2010 04:41:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43446</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently posted briefing documents on its website ahead of the review of Vivus’ (VVUS) obesity drug Qnexa by the FDA’s Endocrinologic &#38; Metabolic Drugs Advisory Committee. While the FDA said that all three doses of Qnexa were efficacious for weight loss, the agency has raised questions regarding certain safety issues. The FDA has highlighted five areas which will be discussed by the panel. These include psychiatric-related and cognitive-related adverse events, metabolic acidosis, cardiovascular events and the effect of the drug on pregnant women. We believe the main focus will be on increased adverse event reports of depression, anxiety, and sleep disorders and the potential clinical significance of the increase in heart rate. The advisory panel will be meeting on Jul 15 to discuss ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/14/vvus-fda-to-review-vivus-drug/43446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review</title>
		<link>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187</link>
		<comments>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32187</guid>
		<description><![CDATA[Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/vvus-vivus-obesity-drug-application-for-qnexa-to-get-fda-review/32187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Obesity Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994</link>
		<comments>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994#comments</comments>
		<pubDate>Thu, 25 Feb 2010 23:18:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28994</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies. The decision is based on encouraging 52-week results on the combination treatment from a blinded, placebo-controlled phase II extension study in which the combination succeeded in achieving the key target of sustained and robust weight loss. Results showed that patients who continued treatment with pramlintide/metreleptin for 52 weeks experienced sustained weight loss, while those on placebo regained almost all of their weight. The combination treatment was found to be most effective in patients with a body mass index (BMI) less than 35 kg/m2. The combination treatment was generally well tolerated, with nausea and injection-site-adverse events being the most common side effects ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/amln-amylin-pharmaceuticals-obesity-drug-pipeline-advances/28994/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck &amp; Co Ends Deal with Arena Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734</link>
		<comments>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:11:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23734</guid>
		<description><![CDATA[Merck &#38; Co (MRK) recently informed its partner Arena Pharmaceuticals (ARNA) that it was pulling out of a collaboration agreement pertaining to the development of an atherosclerosis drug. The decision by Merck to discontinue the development of the candidate, MK-1903, a niacin receptor agonist for treating atherosclerosis, followed disappointing results from a recently completed mid-stage study. The randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability and potential efficacy in patients with dyslipidemia. The study did not meet the primary objective for efficacy. The drug failed to significantly raise patients&#8217; levels of good cholesterol (HDL) compared to a placebo. However, Merck’s decision to pull out of the deal was not related to any safety concerns pertaining to the drug. Atherosclerosis is the thickening of the artery walls which often leads to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/mrk-merck-co-ends-deal-with-arena-pharmaceuticals/23734/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Amylin Pharmaceuticals Strikes First on Obesity</title>
		<link>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415</link>
		<comments>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:30:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19415</guid>
		<description><![CDATA[Almost all of the news in the obesity race has been made recently by three small biotech companies &#8212; Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race. Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesity. As part of the transaction, Amylin will receive a one-time up-front payment of $75 million from Takeda. Amylin is also eligible to receive additional payments based on development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/arna-amylin-pharmaceuticals-strikes-first-on-obesity/19415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARNA) Arena Pharmaceuticals&#8217; Lorcaserin Has Safety Edge</title>
		<link>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751</link>
		<comments>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751#comments</comments>
		<pubDate>Mon, 21 Sep 2009 17:19:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Arena Pharmaceuticals]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15751</guid>
		<description><![CDATA[Results from Arena Pharmaceuticals’ (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/21/arna-arena-pharmaceuticals-lorcaserin-has-safety-edge/15751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

